MedTrace Logo

Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

NCT04918173 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-11-21

No results posted yet for this study

Summary

The goal of this study is to assess the incidence of the composite of thrombotic events (TEs) and thromboembolic events (TEEs) in patients with congenital antithrombin deficiency under when they receive Atenativ for surgical procedures or parturition.

Conditions

  • Congenital Antithrombin Deficiency

Interventions

DRUG

Atenativ

Antithrombin concentrate

Sponsors & Collaborators

  • Octapharma

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2026-06-01
Completion
2026-06-01
FDA Drug
Yes

Countries

  • United States
  • Armenia
  • Austria
  • Czechia
  • France
  • Georgia
  • Germany
  • Hungary
  • Israel
  • Italy
  • Romania
  • Serbia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04918173 on ClinicalTrials.gov